These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


Pubmed for Handhelds

PUBMED FOR HANDHELDS

Journal Abstract Search

86 related items for PubMed ID: 3018229

  • 1. In vivo and in vitro effects of WR-2721 in experimental hypercalcemia in the rat.
    Weiss J, Walker ST, Fallon M, Goldfarb S.
    J Pharmacol Exp Ther; 1986 Sep; 238(3):969-73. PubMed ID: 3018229
    [Abstract] [Full Text] [Related]

  • 2. Bone and parathyroid inhibitory effects of S-2(3-aminopropylamino)ethylphosphorothioic acid. Studies in experimental animals and cultured bone cells.
    Attie MF, Fallon MD, Spar B, Wolf JS, Slatopolsky E, Goldfarb S.
    J Clin Invest; 1985 Apr; 75(4):1191-7. PubMed ID: 2985652
    [Abstract] [Full Text] [Related]

  • 3. Resorbing bone stimulates tumor cell growth. A role for the host microenvironment in bone metastasis.
    Manishen WJ, Sivananthan K, Orr FW.
    Am J Pathol; 1986 Apr; 123(1):39-45. PubMed ID: 3457536
    [Abstract] [Full Text] [Related]

  • 4. WR-2721 reduces bone loss after hindlimb tenotomy in rats.
    Shaker JL, Fallon MD, Goldfarb S, Farber J, Attie MF.
    J Bone Miner Res; 1989 Dec; 4(6):885-90. PubMed ID: 2558504
    [Abstract] [Full Text] [Related]

  • 5. Normalization of hypercalcemia associated with a decrease in renal calcium reabsorption in Leydig cell tumor-bearing rats treated with WR-2721.
    Hirschel-Scholz S, Caverzasio J, Rizzoli R, Bonjour JP.
    J Clin Invest; 1986 Jul; 78(1):319-22. PubMed ID: 3013941
    [Abstract] [Full Text] [Related]

  • 6. Mechanism of the hypocalcemic agent WR-2721 and its acute and chronic application in eu- and hyperparathyroidism.
    Hirschel-Scholz S, Caverzasio J, Bonjour JP.
    Adv Exp Med Biol; 1986 Jul; 208():367-70. PubMed ID: 3031946
    [No Abstract] [Full Text] [Related]

  • 7. 1alpha(OH)D3 One-alpha-hydroxy-cholecalciferol--an active vitamin D analog. Clinical studies on prophylaxis and treatment of secondary hyperparathyroidism in uremic patients on chronic dialysis.
    Brandi L.
    Dan Med Bull; 2008 Nov; 55(4):186-210. PubMed ID: 19232159
    [Abstract] [Full Text] [Related]

  • 8. Promotion of cystine uptake, increase of glutathione biosynthesis, and modulation of glutathione status by S-2-(3-aminopropylamino)ethyl phosphorothioic acid (WR-2721) in Chinese hamster cells.
    Issels RD, Nagele A.
    Cancer Res; 1989 Apr 15; 49(8):2082-6. PubMed ID: 2539252
    [Abstract] [Full Text] [Related]

  • 9. Treatment of hypercalcemia in parathyroid cancer with WR-2721, S-2-(3-aminopropylamino)ethyl-phosphorothioic acid.
    Glover DJ, Shaw L, Glick JH, Slatopolsky E, Weiler C, Attie M, Goldfarb S.
    Ann Intern Med; 1985 Jul 15; 103(1):55-7. PubMed ID: 2988391
    [Abstract] [Full Text] [Related]

  • 10. Effect of a single injection of two new bisphosphonates on the hypercalcemia and hypercalciuria induced by Walker carcinosarcoma 256/B in thyroparathyroidectomized rats.
    Kozak S, Rizzoli R, Trechsel U, Fleisch H.
    Cancer Res; 1987 Dec 01; 47(23):6193-7. PubMed ID: 3677071
    [Abstract] [Full Text] [Related]

  • 11. Hypocalcaemic effect of WR-2721, S-2 (3-aminopropylamino) ethyl-phosphorothioic acid in an anuric haemodialysis patient.
    Zingraff J, Bourdeau A, Clair F, Kindermans C, Buisson C, Manganella G, Sachs C, Drüeke T.
    Nephrol Dial Transplant; 1987 Dec 01; 2(1):48-52. PubMed ID: 3037448
    [Abstract] [Full Text] [Related]

  • 12. Management of hypercalcemia in relation to pathophysiology.
    Bonjour JP, Rizzoli R, Hirschel-Scholz S, Caverzasio J.
    Bone; 1987 Dec 01; 8 Suppl 1():S29-33. PubMed ID: 2825740
    [Abstract] [Full Text] [Related]

  • 13. Therapeutic efficacy of a soluble receptor activator of nuclear factor kappaB-IgG Fc fusion protein in suppressing bone resorption and hypercalcemia in a model of humoral hypercalcemia of malignancy.
    Oyajobi BO, Anderson DM, Traianedes K, Williams PJ, Yoneda T, Mundy GR.
    Cancer Res; 2001 Mar 15; 61(6):2572-8. PubMed ID: 11289133
    [Abstract] [Full Text] [Related]

  • 14. Suramin suppresses hypercalcemia and osteoclastic bone resorption in nude mice bearing a human squamous cancer.
    Yoneda T, Williams P, Rhine C, Boyce BF, Dunstan C, Mundy GR.
    Cancer Res; 1995 May 01; 55(9):1989-93. PubMed ID: 7728770
    [Abstract] [Full Text] [Related]

  • 15. Interference of WR-2721 with magnesium metabolism: mechanism of action.
    Hirschel-Scholz S, Paunier L, Bonjour JP.
    Miner Electrolyte Metab; 1988 May 01; 14(2-3):114-20. PubMed ID: 2837628
    [Abstract] [Full Text] [Related]

  • 16. Inhibition of prostate cancer metastasis in vivo: a comparison of 1,23-dihydroxyvitamin D (calcitriol) and EB1089.
    Lokeshwar BL, Schwartz GG, Selzer MG, Burnstein KL, Zhuang SH, Block NL, Binderup L.
    Cancer Epidemiol Biomarkers Prev; 1999 Mar 01; 8(3):241-8. PubMed ID: 10090302
    [Abstract] [Full Text] [Related]

  • 17. A vitamin D analogue (EB1089) inhibits parathyroid hormone-related peptide production and prevents the development of malignancy-associated hypercalcemia in vivo.
    Haq M, Kremer R, Goltzman D, Rabbani SA.
    J Clin Invest; 1993 Jun 01; 91(6):2416-22. PubMed ID: 8514854
    [Abstract] [Full Text] [Related]

  • 18. [Role of calcitonin in pregnant rats : interaction with 1,25-dihydroxycholecalciferol on fetal bone resorption in vivo/in vitro].
    Rebut-Bonneton C, Martin JL, Miravet L, Amor B.
    C R Seances Acad Sci III; 1983 Jan 10; 296(1):63-6. PubMed ID: 6404511
    [Abstract] [Full Text] [Related]

  • 19. Isolation and identification of 1alpha-hydroxy-3-epi-vitamin D3, a potent suppressor of parathyroid hormone secretion.
    Brown AJ, Ritter CS, Weiskopf AS, Vouros P, Sasso GJ, Uskokovic MR, Wang G, Reddy GS.
    J Cell Biochem; 2005 Oct 15; 96(3):569-78. PubMed ID: 16088954
    [Abstract] [Full Text] [Related]

  • 20. Increased renal calcium reabsorption by parathyroid hormone-related protein is a causative factor in the development of humoral hypercalcemia of malignancy refractory to osteoclastic bone resorption inhibitors.
    Onuma E, Azuma Y, Saito H, Tsunenari T, Watanabe T, Hirabayashi M, Sato K, Yamada-Okabe H, Ogata E.
    Clin Cancer Res; 2005 Jun 01; 11(11):4198-203. PubMed ID: 15930357
    [Abstract] [Full Text] [Related]

    Page: [Next] [New Search]
    of 5.